A novel elementary osmotic pump tablet was developed. The system uses the core of drug-resin complexes (DRCs) loaded with propranolol hydrochloride (PNH) for time-controlled delivery. In traditional osmotic pump tablets (OPTs), the lag time was always minimized. However, in the DRCs osmotic pump tablet (DRCOPT), the lag time was increased to achieve the time-controlled delivery. The quantity of osmotic agent in the core and channeling agent in the coating solution as well as weight gain were conˆrmed to be essential for the release behavior. A spherical symmetric design was applied to the optimization of the DRCOPT. The optimal formulation mainly consisted of DRC 100 mg, polyethyleneoxide (N80) 182 mg, and NaCl 30 mg. The ratio of cellulose acetate (CA)/polyethylene glycol 4000 was 15：3 (w/w) in coating solution, and the weight gain was 8％. The release behavior of the optimal DRCOPT was evaluated in media with diŠerent pH, rotation speeds, and ionic strength. It was found to generate a 2-h lag time, to deliver PNH at a rate of zero order from 2 h to 14 h in the medium of NaCl 0.15 mol/l, and the cumulative release at 24 h was 94％. Drug relee was independent of pH and rotation speed, but was proportional to ionic strength. In summary, the lag time could be used in therapeutic regimens with the characteristics of chronotherapy because of the lag time and provides a new concept for the development of osmotic pumps.
INTRODUCTION
The osmotic pump tablet (OPT) is an advanced drug-delivery technology that uses osmotic pressure as the driving force to deliver pharmacotherapy, usually once daily, in several therapeutic areas, which was developed as an oral drug-delivery system. In the historical development of the OPT, there were many achievements for its promotion, including the RoseNelson pump, 1) Higuchi-Leeper pump, 2, 3) elementary osmotic pump tablet (EOPT), 4) and push-pull system. 5) In recent years, many novel technologies and formulations related to the OPT have been developed, such as osmotic drug delivery using swellablecore technology, 6) eŠervescent OPT from a traditional Chinese medicine compound recipe, 7) (SBE)7m-b-CD in controlled-porosity OPT, 8) and other new approaches.
Ion-exchange resins (IERs) are crosslinked waterinsoluble polymers carrying ionizable functional groups. The resins have been used in various pharmaceutical applications, primarily for taste masking and for controlled-release systems in liquid or solid form. 9 11) IERs behave, for some drugs, as reliable, controlled drug-delivery systems. 12) However, improvements of their release properties can be aŠected by coating the resin beads and further controlling the rate of drug release. 13 16) In these forms, the pattern of drug release is governed by the degree of crosslinking of the resins and by the properties of the coat.
Propranolol hydrochloride (PNH) was chosen as the model drug. PNH is a nonselective Beta-adrenergic blocking agent and has been widely used in the treatment of hypertension, angina pectoris, and many other cardiovascular disorders. 17) Patients with cardiovascular disease are at the greatest risk of heart attack and stroke during the early hours of the morning (02:00), and there is a need for adequate control of hypertension during this vulnerable period. It is necessary to develop a time-controlled system to achieve an eŠective drug level only at the demanded time.
In previous studies, drug-resin complex (DRCs) have been employed in controlled release with numer-ous types of materials such as poly (4-vinylpyridine), sulphonic acid cation-exchange resin, and sodium polystyrene sulfonate, and there were several reports on PNH-resin complexes, for example, calcium alginate beads loaded with PNH-resin complexes, 18) poly (acrylic acid) grafted poly (vinylidene ‰uoride) membrane, 19) and polymeric microparticles. 20) Thê rst report concerning the use of a DRC to modulate osmotic pump tablets was published in 1990. 21) Furthermore, the eŠects of IERs on the release of PNHmatrix tablets were studied in 1998. 22) The paper focused on the combination of an OPT and IER to prepare a novel osmotic pump tablet for time-controlled delivery. Unlike other EOPT systems, 23, 24) this delivery system showed a steady zero-order release proˆle after an initial lag time, which is the diŠerence between the DRCOPT and other approaches.
In this study, cores consisting mainly of DRCs, polyethyleneoxide (PEO), and sodium chloride were coated with a semipermeable membrane and an oriˆce was drilled. A 2-h lag time was observed and steadier drug release behavior was achieved in in vitro experiments. The DRCOPT not only improved the application of the OPT in the direction of time-controlled release by combinating the EOPT and IER, but also controlled the drug-release rate. In addition, the lag time provided a new concept for preparing a novel EOPT for a time-controlled system. It could also provide a method to achieve an eŠective drug level only at the demanded time using the DRCOPT.
MATERIALS AND METHODS

Materials
Propranolol HCl (Rouz Darou Co.) and the cation-exchange resin Amberlite IRP69 (sodium polystyrene sulfonate) was obtained from Rohm and Haas Company, Philadelphia, PA, USA; sodium chloride, mannitol, and lactose (Tianjin Bo-di Chemical Industry, Tianjin, China), cellulose acetate (CA, Shanghai Chemical Reagent, Shanghai, China), and hydroxypropylmethylcellulose (HPMC, K4M Colorcon, UK), sodium carboxymethyl cellulose (CMCNa, Colorcon), polyethyleneoxide (PEO, Dow Chemical, NJ, USA), and polyethylene glycol 1500, 4000, and 20000 (PEG, Shenyang Chemical Reagent, Shenyang, China), polycinylpyrrolidone K30, K90, S630 (PVP, ISP Technologies Inc.) were employed in the experiments. All other reagents used were of analytical grade.
PREPARATION OF DRCOPT Preparation of Cores
DRCs were prepared using the batch method. In this experiment, IERs were suspended in a speciˆc concentration of PNH dissolved in deionized water under magnetic stirring at constant temperature and thereafter sampled and the concentration determined at predetermined time points. After exchange reached the balance point, the DRCs were washed free of the exchange salt and any free drug with deionized water. The drug-loaded resin beads obtained were dried in a ‰uid bed at 40°C.
Tableting and Coating
The dried drug-loaded resin beads (100 mg), and other excipients were sieved through 160 mesh separately and mixed (except for magnesium stearate) for 10 min. To the mixture, sieved magnesium stearate (3 mg) was added and the blend continued for 10 m longer. The dried powders were directly compressed using a singlepunch tableting machine (Shanghai Huanghai Drug Inspection Instrument, Shanghai, China) with a 9.0-mm bulgy-faced punch to yeild a 0.33-g tablet each time. The hardness of the tablets was kept constant (3 kg, hardness tester, Idem, Shanghai, China). The tablet core was coated with coating ‰uid composed of diŠerent ratios of CA to PEG, forming a semi permeable membrane. A 0.6 mm oriˆce was drilled on the membrane surface mechanically. In this study, formulation 1 was coated to a weight gain of 6 ％, 8％ and 10％ of the core, respectively, while the other formulations were 8％ of the core. DiŠerent core formulations and coating solutions are listed in Table 1 .
Optimization of the Formulation The spherical symmetric design was applied to optimize the formulation. This experimental design required 15 experiments in total (2 n ＋2n＋1, where n is the number of factors). The ranges of three factors andˆve levels were determined based on preliminary experiments. The cumulative release during 24 h (Q 24 ), linear degree of zero order from 2 h to 14 h by the means of the least-squares method, and ratio of the cumulative release at 16 h (Q 16 ) to that at 24 h (Q 24 ) were set as indexes to optimize the formulations.
In Vitro Drug Release The release of drug from the core of the DRCOPT (equivalent to PNH 40 mg) was determined using the paddle method of the USP Pharmacopoeia Dissolution Apparatus test (50 rpm, 37°C). The dissolution medium (900 ml) was NaCl 
EŠects of Dissolution Medium
To investigate the eŠects of the pH value of the dissolution medium on DRCOPT release behavior, release tests were carried out in 1) simulated gastric ‰uid (SGF), pH 1.2; 2) simulated intestinal ‰uid (SIF), pH 6.8; 3) SGF for 2 h and SIF for up to 24 h; 4) simulated colonic ‰uid (SCF), pH 7.4. 25) All were adjusted to the same ionic strength with NaCl.
EŠects of Ionic Strength Sodium chloride solutions with diŠerent ionic strengths of 0.05 mol/l, 0.10 mol/l, and 0.15 mol/l were prepared to study the eŠects of ionic strength on release behavior.
EŠects of Rotation Speed Dissolution tests were conducted at diŠerent rotation speeds of 50 rpm, 75 rpm, and 100 rpm to investigate the eŠects of rotation speed on release behavior.
Lag Time
To compare the lag time of the DRCOPT with that of the conventional OPT, diŠer-ent tablet cores were designed. One was the optimal the DRCOPT formulation, and the other was the same formulation in which only the DRCs were replaced with PNH with equal PNH content. After being coated with the speciˆc coating solution, both were compared in an in vitro drug release test. At the same time, the DRCOPT cores without coating and DRCs were also examined in the same trial.
RESULTS AND DISCUSSION
In Vitro Characterization of Formulations
In vitro drug release proˆles of diŠerent formulations under sink conditions are shown in Figs. 1 5. As evident from the dissolution proˆles, diŠerences in drug release behaviors were observed with the types and amounts of suspension agent, osmotic agent, binder, composition of coating solution, and weight gain. The similarity factor f 2 was used to evaluate the release behaviors among the diŠerent formulations. 26) 
Where, šx ti and šx ri represent the average percentage of drug released from the three test tablets and three reference tablets at the ith time point, respectively, and T is the number of time points tested. When the two proˆles are identical, f 2 ＝100. An average diŠer-ence of 10％ at all measured time points results in an f 2 value of 50. The US Food and Drug Administration has set a public standard of an f 2 value between 50 and 100 to indicate similarity between two dissolution proˆles.
Restrictions associated with the use of the f 2 estimate include:
1) The dissolution measurements of the test and reference batches must be done under exactly the same conditions.
2) There should only be one measurement considered after either product has achieved 85％ dissolution.
3) The percent coe‹cient of variation (CV) at the earliest points (e.g., 15 min) should not exceed 20％, and the％ CV should not exceed 10％ at all other time points.
An f 2 value of 50 or greater (50 100) ensures the sameness or equivalence of the two curves, and thus the performance of the two products. 27, 28) As shown in Fig. 1 , the cores of PEO (N80) exhibited a better release proˆle compared with those of HPMC ( f 2 ＝24.01), indicating that PEO (N80) had a better suspension function, because in the good suspension agent the DRC was suspended uniformly in the core when water entered. A microenvironment occurrs, in which NaCl gradually exchanges the drug with the DRCs. Thereafter, the exchanged drug is exported from the oriˆce. Although the cores of CMCNa expressed a similar release behavior ( f 2 ＝58.56), the compressibility was inferior to that of PEO (N80). To compare the eŠects of diŠerent types of PEO on release behavior, PEO (N80) was replaced with PEO (N10) and PEO (N750), and similar proles were obtained. The f 2 values with PEO (N80) were 65.70 for PEO (N10) and 60.70 for PEO (N750), respectively, demonstrating that the in‰uence of PEO was minute. As a result, PEO (N80) was chosen as suspension agent in the core.
As shown in Fig. 2 , varying the categories and quantity of osmotic agents in the cores had an obvious eŠect on the release behavior from formulations. Compared with NaCl, drug released from cores of lactose ( f 2 ＝47.45) and mannitol ( f 2 ＝48.88) as osmotic agents appeared to be more incomplete, which could be explained as follows. NaCl has two aspects of function. First, NaCl dissolved in the core created a constant osmotic pressure diŠerence between the core ingredients and external environment, which could produce su‹cient osmotic pressure to guarantee the impetus of drug release. In addition, NaCl is an ionic osmotic agent, which could provide the DRC with Na ＋ to exchange drug, and this may cause the distinction in drug release between NaCl and other nonionic osmotic agents in the DRCOPT. To adjust the appropriate drug release, the quantity of NaCl was also studied to determine whether it in‰uenced the release behavior. It was noted that the cumulative release increased as the quantity of NaCl rose. However, NaCl 30 mg in the core displayed a better zero-order proˆle than 20 mg ( f 2 ＝41.50) and 40 mg ( f 2 ＝71.54).
Because the core contained the DRC, the compressibility was very poor. PVP K30, PVP K90, and PVP S630 were used as binders to improve the compressibility. However, PVP K30 and PVP S630 could not produce su‹cient binding power for direct tableting. As a result, PVP K90 was chosen as the binder. PVP can interfere with the drug release when an inappropriate quantity is used. Figure 3 shows no signiˆcant diŠerences among diŠerent quantities of PVP. As far as the amount of PVP K90 was concerned, the core containing PVP K90 5 mg had poor friability, while the core containing PVP K90 25 mg had high viscosity. Taking tableting and coating into account, 15 mg was chosen as the binder quantity.
In the case of coating factors, the types of PEG and CA/PEG ratio together with the weight gain were investigated to determine the eŠects on the drug release behavior from the same core. When the ratio of CA/ PEG was kept constant, the types of PEG appeared to have an appreciable in‰uence on the drug release rate. As the molecular weight (MW) of PEG increased, the drug release decreased. This is attributed to the dissolution of PEG in the medium, because the speed at which PEG dissolved was inversely proportional to MW. When PEG dissolved, the microspores in the coating membrane appeared, and the rate of water ingress was directly related to the drug release rate. As shown in Fig. 4 , the release proˆle was the same before 10 h, and after that time point, PEG 4000 as the channeling agent manifested an advantage over PEG 1500 ( f 2 ＝63.86) and PEG 20000 ( f 2 ＝46.43), which could be elucidated as follows. In the initial period, all types of PEG have almost the same dissolving rate, and this tendency reached a critical time point, when the disparity in the rate of dissolving increases as the MW of PEG becomes greater. Generally, the components used in the DRCOPT should be common in pharmaceutical products, and therefore PEG 4000 was chosen as the channeling agent. Furthermore, the CA/PEG ratio used in the coating solution had an apparent eŠect on the drug release proˆles because water intake through the coating depended on the quantity of PEG in the coating solution. The f 2 values of the CA/PEG ratio (15：3) between ratio (15：1) and ratio (15：2) were 28.03 and 31.98, respectively. Coatings with the lower CA/ PEG ratio released drug more quickly. The more PEG used in the solution, the more micropores occurred at the same time, leading to higher cumulative release. Thus the CA/PEG ratio can be regarded as a variable to control the drug release proˆle. All the f 2 values given in Figs. 1 4 are the results of other formulations compared with formulation 2 (F: 2).
The general expression for the drug delivery rate from an OPT tablet can be described as the following Eq. (1) of F. Theeuwes. 29) dm/dt＝AS/hLpsDP＋PAS/h (1) Here, A is the OPT surface area, h is the thickness of coating, S is the solubility of drug, Lps is the ‰uid permeability of the coating, P is the permeability coe‹cient of the active ingredient through the coat, and DP is the osmotic pressure diŠerence between the core inside and outer circumstance. From Eq. (1), we can see that the delivery rate is inversely proportional to membrane thickness, and quicker drug release occurs with decreasing coating thickness. For the same cores, coating thickness was related to the coating weight. Figure. 5 shows that the coating weight was a signiˆcant factor governing drug delivery. A comparison of diŠerent weights gain illustrated that the thicker coating had a lower release rate at corresponding time points, because water penetration was slower in cores with a thicker coating, which required a relatively longer time for su‹cient water to ‰uidize the extruded drug. An 8％ weight gain yielded better release behavior; on the contrary, irregular proˆles were obtained when wei ght gain was 6％ ( f 2 ＝39.93) and 10％ ( f 2 ＝37.43) compared with 8％ of the core. This is explained as follows. The thinner coating (6 ％) always re‰ects worse reproducibility, which in turn results in many disadvantages in experimental operation and the further development for practical manufacture. In addition, the drug release proˆle with thicker coating (10％) could contribute to slower drug release, it takes a longer time to carry out the coating operation, and it requires more energy consumption to complete the experiment. Drug release is also hampered by a thicker coating, which may be responsible for the results in Fig. 5 .
Optimization of Formulations Using the Spherical Symmetric Method
According to the results of the in vitro characterization of formulations, the quantity of NaCl in the core, PEG in the coating solution and coating thickness had eŠects on the drug release behavior. That is, osmotic pressure attributes to the quantity of NaCl and CA/PEG ratio, and membrane permeability is attributed to coating thickness and the CA/PEG ratio.
A spherical symmetric design was applied to the optimization of the DRCOPT, and the levels and factors of spherical symmetric design are represented in Table 2.
As mentioned above, the cumulative release during 24 h (Q 24 ) could re‰ect the ultimate release of the DRCOPT. The linear degree of zero order from 2 h to 14 h expressed the minimum value, which was calculated by the sum of the square of distance for each point in the release proˆle to the straight lineˆtted by Excel. The smaller the values, the closer the release behavior approached zero order. The ratio of the cumulative release at 16 h (Q 16 ) to that at 24 h (Q 24 ) showed the drug release during the latter period. Therefore, the three parameters were set as indices to optimize the formulations. The experimental values are summarized in Table 3 .
The purpose of the spherical symmetric design is to deˆne the function relationship between indices investigated and chosen factors, which can be expressed as y＝f( x 1 , x 2 , x 3 , ......) . When applying the equation, the corresponding rule f isˆtted by the regression of x and y, and any function can be extended as a polynomial, and thus f(x)should be assumed to be a polynomial as follows. 30 32) y＝b 0 ＋∑b i x i ＋∑b ij x i x j ＋∑b ijk x i x j x k ＋...... (2) Lingo software 8.0 (Lindo System Inc. USA)was used toˆt each coe‹cient to Eq. (2), as shown in Table 4 .
From the critical value of the F test, the F (n, m n 1) of 99％ signiˆcance level is 6.122, and the F values of the three indices are all greater than 6.122, which means that the polynomialˆtting is reasonable. The limitations of three indices are regulated as follows. Q 24 ( y 1 ) should be greater than 90％, linear degree ( y 2 ) was less than 0.00875 (the optimal valueˆtted by Lingo software), and Q 16 /Q 24 ( y 3 ) was set to be greater than 95％. The regression of Eq. (2) was on the basis of experimental data, and each coe‹cient was obtained. The relationship between indices and factors is given below. The four optimal formulations (Table 5) were obtained from the inequality qualiˆed by the conditions that y 1 ＞0.9, y 2 ＜0.00875, and y 3 ＞0.95. Q 24 , linear degree and Q 16 /Q 24 were anticipated values.
The four distinct formulation principles for the DRCOPT were prepared to verify the results of optimal formulations, which are illustrated in Table 6 and Fig. 6 . It was found that there was good agreement between the experimental and predicted values. In addition, formulation b exhibited better in vitro release behavior, which was in line with every index. As a result, formulation b was determined to be the optimal formulation. In other words, there were DRCs 100 mg, PEO (N80) 182 mg, NaCl 30 mg and PVP K90 15 mg in the core. The ratio of CA/PEG 4000 was 15：3 in coating solution and the weight gain was 8％.
EŠects of Dissolution Medium
To elucidate the eŠect of the dissolution medium on the DRCOPT release characteristics, the release proˆle of the optimal formulation in diŠerent media was obtained. The results were not statistically signiˆcant ( p＜ 0.05). As illustrated in Fig. 7 linear correlation of zero order could be achieved in diŠerent pH gradients, indicating that the release behavior of the DRCOPT was not aŠected by the simulated pH en- vironment in the human body, which was consistent with the characteristics of the OPT.
EŠects of Ionic Strength
The drug release studies were performed in sodium chloride solution of diŠerent ionic strengths. Based on the results shown in Fig. 8 , drug release exhibited consonance before 6 h, when the cumulative release began to increase as the ionic strength increased. A possible reason for the eŠect of ionic strength on drug release is that when water entered the core through the semipermeable membrane, PEO (N80) swells gradually. During thê rst 6 h, PEO (N80) acts as an excellent suspension agent, which provides NaCl with the proper conditions to exchange PNH in the core. Thereafter, the exchanged drug is released from the oriˆce under the osmotic pressure. The more water taken in, the more the PEO swells. A portion of the DRCs are driven away to the medium solution. It was noted that greater ionic strength provides the DRCs with more opportunities to exchange drug. Consequently, the DRC expelled in higher ionic strength solution exhibited a better release proˆle than that in lower ionic strength solution.
EŠects of Rotation Speed
To investigate the eŠects of stirring speed on the drug release behavior, dissolution experiments with the optimal DRCOPT were carried out at stirring rates of 50, 75, and 100 rpm. As shown in Fig. 9 , no signiˆcant eŠect of rotation speed on the drug release proˆle was observed. Thus the mobility of the gastrointestinal tract may only slightly aŠect the drug release of the DRCOPT, meaning that the DRCOPT will remain in the gastrointestinal tract in a reliable and reproducible manner.
Evaluation of Lag Time in the DRCOPT Delivery System
Lag time is a normal phenomenon in the OPT delivery system. In previous studies, the main purpose was always to shorten the lag time. On the contrary, the lag time was utilized to achieve the aim of time-controlled delivery system in this investigation.
Compared with the conventional OPT, the DRCOPT gained an advantage in terms of lag time. Figure 10 shows the release proˆles of diŠerent formulations, and the release rate increased from resinloaded drug (PNH) to the DRCOPT. When the DRCs were exposed to the dissolution medium, the exchange reaction occurred immediately, the cumulative release was 98.43％ within 2.5 h, and rapid release behavior can be achieved. As for the DRC tablet, a relatively slower drug release rate was observed, because the DRC tablet was a type of matrix tablet with PEO (N80) as the hydrophilic matrix material. Furthermore, drug release from conventional OPT and DRCOPT formulations could be controlled and the DRCOPT sustained a longer zero-order drug release period, ranging from 2 h to 14 h, than that of the conventional OPT, ranging from 0 h to 10 h. Additionally, the DRCOPT had a 2-h lag time in the in vitro dissolution test, which may accommodate such diseases as hypertension and angina pectoris occurring during certain period.
In the current study, the lag time was due to two factors. On one hand, the in‰ux of water into tablets customarily requires a certain time. On the other hand, the DRCs in cores that exchanged drug with sodium chloride also consumed time. As a result, a relatively longer lag time of the DRCOPT compared to the conventional OPT occured.
CONCLUSIONS
A time-controlled release system that met the requirements for chronopharmaceutical drug delivery was developed based on the combination of the DRC and OPT. The quantity of osmotic agent in the core and channeling agent in the coating solution as well as weight gain were shown to be essential for the release behavior. Compared with other formulations, an obvious lag time was achieved. The system can be used in therapeutic regimens for diseases with characteristics of chronotherapy. In further investigations, more experiments are needed to describe the in vivo release behavior. On the whole, the DRCOPT preparation will provide a novel method for time-controlled delivery systems and provide a new concept for the development of osmotic pumps.
